Therapeutics and Clinical Risk Management

Professor Garry Walsh

Professor Walsh

Emeritus Reader in Inflammation & Immunity, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom

Dr. Walsh is reader in Inflammation and Immunity and principal investigator of the Asthmatic and Allergic Inflammation Group, School of Medicine and Dentistry, University of Aberdeen, UK. His group is part of the Immunology Research Programme, within the Division of Applied Medicine that was rated fourth equal in the UK in the 2008 research assessment exercise.

Dr. Walsh is honorary professor of inflammation and immunity, School of Medicine, Trinity College, Dublin, Ireland. His major research interests involve elucidation of the molecular mechanisms controlling the initiation and resolution of the inflammatory processes underlying asthma, COPD and allergic disease.

Dr. Walsh has published over 60 peer-reviewed articles in international journals together with more than 60 invited editorials, reviews and book chapters. To date these publications have been cited over 3,300 times, giving an h-index of 33 (source ISI Web of Knowledge). Dr. Walsh has been an invited speaker and/or chairman at over fifty international meetings.

In addition to his role as the editor-in-chief of Therapeutics and Clinical Risk Management he is the founding editor of the Journal of Cell Death, and Clinical Medicine - Therapeutics. He is also an editorial board member of the Journal of Allergy (section head), International Journal of Biomedical Science, Biologics: targets and therapy, The Open Immunology Journal, The Open Inflammation Journal, The Open Allergy Journal and the Journal of Organ Dysfunction.

Dr. Walsh is a regular reviewer for over 40 clinical and scientific journals and serves as a grant reviewer for UK and international funding bodies. Since 2003 he has been a European Commission evaluation expert for FP6 and FP7 and is currently vice-chair of the Evaluation Panel for Marie Curie Mobility Actions. Dr Walsh is a member of the MRC College of Experts affiliated to the Infection and Immunity Board and a member of Lung Cellular and Molecular Immunology (LCMI) Special Emphasis Panel, National Institutes of Health USA.

Dr Sandeep Ajoy Saha

Dr Saha

Dr Saha, Oregon Heart Center, Salem Health Hospitals and Clinics, Salem, Oregon, USA

Dr Sandeep Saha, MD, MS, FACC, FHRS is a clinical cardiologist and cardiac electrophysiologist and serves as Director of Cardiac Electrophysiology and Arrhythmia Services at the Oregon Heart Center, and is a consultant in cardiology and clinical cardiac electrophysiology at Salem Health Hospitals and Clinics in Salem, Oregon, USA. He was previously held faculty positions at the University of Washington School of Medicine in Seattle, and was a clinical investigator at the Providence Medical Research Center in Spokane, Washington.

Dr Saha has been involved in basic, clinical, and translational research studies over the course of his career, and has authored over 80 peer-reviewed publications including original research papers, conference presentations, textbook chapters, and invited editorials. He was Editor of a 2-volume textbook on current advances in cardiovascular risk, and is currently working as Associate Editor of a new textbook of clinical cardiac electrophysiology.

Dr Saha serves as a peer reviewer for more than 25 prestigious medical journals that encompass the fields of general internal medicine, cardiovascular diseases, cardiac electrophysiology, clinical pharmacology and therapeutics, and digital solutions for healthcare delivery and medical education. He also serves as a consultant, advisory board member, and invited speaker for several medical companies, and is an active member of various committees within the Heart Rhythm Society (HRS) and the American College of Cardiology (ACC).

Dr Saha is an ardent supporter of the open-access publishing model for timely and widespread dissemination of medical research, while simultaneously upholding the scientific rigor and integrity of the peer-review and editorial process.

As Associate Editor-in-Chief of Therapeutics and Clinical Risk Management, Dr Saha looks forward to contributing to the mission of the journal and continue to attract and publish high-quality research from all over the world.

Professor De Yun Wang

Professor Wang

Department of Otolaryngology, National University of Singapore, National University Health System, Singapore

Dr. Deyun Wang is a Research Professor (tenure) and Director of Research, Department of Otolaryngology at the National University of Singapore and a member of the Research Task Force and Deputy Chair of the NUS Medicine Safety Committee. He is the International President of the Portmann Institute (France, October 2018-October 2021).

Dr Wang has published over 350 peer-reviewed papers in prestigious medical journals (e.g., Science, Cell, Nature Biology, Allergy, Journal of Allergy and Clinical Immunology) and over 30 book chapters. He is an Associate Editor of Allergy, Military Medical Research, International Archives of Allergy and Immunology, and member of the editorial boards of more than twenty allergy, ENT and medical journals. 

Dr Wang is a member of expert committees for European White Paper in Allergy, WHO Initiative – Allergic Rhinitis and its Impact on Asthma (ARIA 2001 and ARIA 2008), European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS, 2007, 2012, 2020), International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (2016, 2021), and International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018).